Activation and inhibition of the immune system

Details Activation and inhibition of the immune system Activation and inhibition of the immune system

2011-03-29

2011-03-29

Leavitt, Maria (Department: 1633)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S069200, C435S252300, C435S320100, C435S325000

Reexamination Certificate

active

07915009

ABSTRACT:
Activation of the immune response by NF-kB inducers, induction of an anergic response by NF-kB inhibitors and the inhibition and activation of immune response by the administration of an activator or inhibitor of NF-kB is disclosed. Examples of NF-kB inhibitors include IkBα, PSI, a nucleotide sequence encoding IkBα anti-sense nucleic acid encoding an NF-kB sequence, such as Rel B, and anti-NF-kB antibodies. Examples of NF-kB inducers include NIK, MEKK, IKK2, TFRRF2, and Rel B. Also disclosed are vectors encoding inducers and inhibitors of NF-kB, for example adenoviral vectors.

REFERENCES:
patent: 4987071 (1991-01-01), Cech et al.
patent: 5093246 (1992-03-01), Cech et al.
patent: 5116742 (1992-05-01), Cech et al.
patent: 5149796 (1992-09-01), Rossi et al.
patent: 5168053 (1992-12-01), Altman et al.
patent: 5180818 (1993-01-01), Cech et al.
patent: 5854043 (1998-12-01), Johnson
patent: 5891924 (1999-04-01), Aggarwal
patent: 5951988 (1999-09-01), Littel-van den Hurk et al.
patent: 6294378 (2001-09-01), Houghton et al.
patent: 6410516 (2002-06-01), Baltimore et al.
patent: 6503184 (2003-01-01), Ni et al.
patent: 6528482 (2003-03-01), Anderson et al.
patent: 2003/0125235 (2003-07-01), Foxwell et al.
patent: 2003/0153518 (2003-08-01), Foxwell et al.
patent: 2004/0086516 (2004-05-01), Foxwell et al.
patent: 2004/0241152 (2004-12-01), Foxwell et al.
patent: 2006/0063697 (2006-03-01), Gabrilovich et al.
patent: 0 779 361 (1997-06-01), None
patent: 0779361 (1997-06-01), None
patent: 0 894 855 (1999-02-01), None
patent: 0 897 009 (1999-02-01), None
patent: 0894855 (1999-02-01), None
patent: 0897009 (1999-02-01), None
patent: 06-209778 (1994-08-01), None
patent: 11-071278 (1999-03-01), None
patent: 2002-513552 (2002-05-01), None
patent: WO 91/06571 (1991-05-01), None
patent: WO 92/07573 (1992-05-01), None
patent: WO 94/24281 (1994-10-01), None
patent: WO 95/31483 (1995-11-01), None
patent: WO 96/03144 (1996-02-01), None
patent: 96/25666 (1996-08-01), None
patent: 97/01340 (1997-01-01), None
patent: 97/37016 (1997-10-01), None
patent: 98/06692 (1998-02-01), None
patent: 98/08955 (1998-03-01), None
patent: 98/28424 (1998-07-01), None
patent: 99/57133 (1999-01-01), None
patent: 99/06009 (1999-02-01), None
patent: WO 99/13064 (1999-03-01), None
patent: 99/27112 (1999-06-01), None
patent: 99/42137 (1999-08-01), None
patent: 99/65449 (1999-12-01), None
patent: WO 00/26249 (2000-05-01), None
Pettit et al., Nuclear localization of ReIB is associated with effective antigen-presenting cell function. J Immunol. Oct. 15, 1997;159(8):3681-91.
Foxwell et al.,Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci U S A. Jul. 7, 1998;95(14):8211-5.
Calder et al., Antigen-specific T-cell downregulation by human dendritic cells following blockade of NF-kappaB.Scand J Immunol. Mar. 2003;57(3):261-70. Abstract PMID 12641655.
Yoshimura et al., Antigen presentation by murine dendritic cells is nuclear factor-kappa B dependent both in vitro and in vivo.Scand J Immunol. Aug. 2003;58(2):165-72.
Foxwell et al., High efficient gene transfer is an efficient way of defining therapeutic targets:a functional genomics approach. 2001, Ann Rhem Dis. 60:iii13-iii17.
Karin et al., hosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621-63. Review.
Goodman and Gilman's The Pharmacological Basis of Therapeutics. Ninth Edition McGraw-Hill 1996 pp. 77-101.
Sharma et al., Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and . Gene Ther. 1997 4:1361-70.
Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, Dec. 1995 p. 24.
Gene Therapy's Growin Pains, Science. 1995, 25:1050, 1052-5.
Scientific Considerations Related to Developing Follo-On Protein Products. Division of Dockets Management U.S. Food and Drug Administration Nov. 12, 2004, pp. 1-12.
Wang et al., Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination.Hum Gene Ther. Jul. 20, 1997;8(11):1355-63.
Rothe M Activation of NF-κB by inflammatory Cytokines, 1999, Sympsium in Immunology VIII, pp. 31-42.
Tsatsanis et al., Tpl-2 induces IL-2 expression in T-cell lines by triggering multiple signaling pathways that activate NFAT and NF-kappaB. Oncogene. Nov. 19, 1998;17(20):2609-18.
Guo et al., Antisense IRAK-2 oligonucleotide blocks IL-1-stimulated NF-kappaB activation and ICAM-1 expression in cultured endothelial Inflammation. Dec. 1999;23(6):535-43 cells.
Zhang et al., Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes.J Biol Chem. Mar. 19, 1999;274(12):7611-4.
Granelli-Piperno A, et al., Coexpression of NF-kappa B/Rel and Sp1 transcription factors in human immunodeficiency virus 1-induced, dendritic cell-T-cell syncytia Proc Natl Acad Sci U S A. Nov. 21, 1995;92(24):10944-8.
Tillman et al., Maturation of Dendritic Cells Accompanies High-Efficiency Gene Transfer by a CD4O-Targeted Adenoviral Vector The Journal of Immunology, 1999, 162: 6378-6383.
Foxwell et al.,High efficiency gene transfer is an efficient way of defining therapeutic targets: a functional genomics approach Ann Rheum Dis 2001;60:iii13-iii17.
Lee et al., Cyclosporine a Inhibits the Expression of Costimulatory Molecules on in Vitro-Generated Dendritic Cells: Association with Reduced Nuclear Translocation of NuclearTransplantation, Nov. 15, 1999; 68 (9): 1255-63.
Brown MD, Schatzlein AG, Uchegbu IF.Gene delivery with synthetic (non viral) carriers. Int J Pharm. Oct. 23, 2001;229(1-2):1-21.
Eck et al., 1996 Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, p. 77-101.
Gorecki et al., 2001, Prospects and problems of gene therapy: an update Expert. Opin. Emerging Drugs, 6: 187-198.
Banchereau et al., Dendritic cells and the control of immunity Nature, 1998 pp. 245-252.
Ashley et al. “Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors” J. Exp. Med. 186:1177-1182 (1997).
Baeuerle & Baltimore “NF-κB: Ten years after” Cell 87:13-20 (1996).
Baeuerle & Henkel “Function and activation of NF-κB in the immune system” Ann. Rev. Immunol. 12:141-179 (1994).
Beauparlant & Hiscott “Biological and biochemical Inhibitors of the NF-κB/Rel proteins and cytokine synthesis” Cytokine & Growth Factor Reviews 7:175-190 (1996).
Bender et al. “Improved methods for the generation of dendritic cells from nonproliferation progenitors in human blood” J. Immunol. 196:121-135 (1996).
Bohl et al. “Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector” Blood 92:1512-1517 (1998).
Boldin et al. “Self-association of the “death domains” of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects” J. Biol. Chem. 270:387-391 (1995).
Bondeson et al. “Defining therapeutic targets by using adenovirus: Blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators” Proc. Natl. Acad. Sci. USA 96:5668-5673 (1999).
Bondeson et al. “Selective regulation of cytokine induction by adenoviral gene transfer of IκBα into human macrophages: Lipopolysaccharide-induced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is nuclear factor-κB independent” J. Immunol. 162:2939-2945 (1999).
Büeler “Adeno-associated viral vectors for gene transfer and gene therapy” Biol. Chem. 380:613-

Affiliated with

Also associated with

Rating

Activation and inhibition of the immune system does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Activation and inhibition of the immune system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activation and inhibition of the immune system will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2730065